Company Description
Monoclonal antibodies and small molecules? Feh! Archemix is focused on aptamers, a type of synthetic oligonucleotide that the drug discovery...
Key Archemix Financials
| Company Type | Private - NASDAQ (GM): ARCH Proposed Main Headquarters |
|---|---|
| Fiscal Year-End | December |
| 2006 Sales (mil.) | $6.4 |
| 2006 Employees | 74 |
More Archemix Financials (4 pages)
Latest Archemix Jobs jobs by Indeed
Competition
Competitive Landscape for Biotechnology Sector
Demand for biotechnology products and services is driven primarily by the willingness of insurers to pay for new medical treatments. The profitability of individual companies depends on the...
Read more about Archemix's competition across multiple industries
Top Archemix Competitors
Sponsored Links
The Business DirectoryTrading Toolbox
Archemix Executives sponsored by genius.com
| Title | Name & Bio | Contact |
|---|---|---|
| President, CEO, and Director | Errol B. De Souza | Network | E-mail |
| VP, CFO, Secretary, and Treasurer | Gregg D. Beloff | Network | E-mail |
| CTO | Charles Wilson | Network | E-mail |
| Are You Listed On Hoover's? | ||
|---|---|---|
| Hoover's subscribers also get access to information on people who have self-listed with this company. Subscribers also have the option to add themselves to this company record. |
Tools from our advertising partners:
Current Archemix News
- APTAMERS TO THE HUMAN IL-12 CYTOKINE FAMILY AND THEIR USE AS AUTOIMMUNE DISEASE THERAPEUTICS [European Patents] (01 Jul 2008 13:09:00 EDT)
- APTAMERS THAT BIND THROMBIN WITH HIGH AFFINITY [European Patents] (17 Jun 2008 12:17:00 EDT)
Latest Industry Video
-
Rx For Cheap Drugs (4:04)
07/23/07 5:20PM ET - Miller Tabak & Co. Pharmaceuticals Analyst Les Fundleyder and Bain & Company Partner Tim Van Biesen discuss patent expirations affecting U.S. drug costs.